nab1-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).

Trial Profile

nab1-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Capecitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms LAPACT
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 20 Jan 2018 Results (n=106) assessing the efficacy and safety of an induction phase regimen of nab-paclitaxel + Gemcitabine in previously untreated patients with locally advanced pancreatic cancer, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 19 Jan 2018 Primary endpoint (Time to Treatment Failure) has been met, according to a Celgene Corporation media release.
    • 19 Jan 2018 Results presented in a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top